Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
November 11, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
-Preclinical data highlight Jounce’s approach to identify potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064- -Enrollment in Phase 1 monotherapy...